Moderna and Merck announced on August 19 that their jointly developed personalized mRNA cancer vaccine, intismeran, met both its primary and key secondary endpoints in a Phase 3 clinical trial involving 1,137 melanoma patients. The treatment reduced cancer recurrence and prevented the spread of disease to other parts of the body in patients whose tumors had been surgically removed, marking the first time a personalized cancer vaccine has produced positive results at this stage of clinical testing.
Key Takeaways
- The Phase 3 INTerpath-001 trial found that intismeran combined with Merck’s immunotherapy drug Keytruda achieved statistically significant improvements in both recurrence-free survival and distant metastasis-free survival compared with Keytruda alone.
- The trial enrolled 1,137 patients with completely resected stage IIB through IV cutaneous melanoma who had not received prior systemic therapy, randomized 2:1 to receive intismeran plus Keytruda or Keytruda alone.
- Earlier Phase 2b data showed the combination cut the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared with Keytruda alone.
- Moderna’s stock surged as much as 177% on the announcement; Merck shares rose 13%.
- Moderna and Merck have eight total Phase 2 and Phase 3 studies underway across melanoma, non-small cell lung cancer, bladder cancer, renal cell carcinoma, and other tumor types.
The Trial Represents a First for Personalized Cancer Immunotherapy
The INTerpath-001 trial is the first randomized Phase 3 clinical study designed to definitively test whether a personalized neoantigen vaccine can improve outcomes for cancer patients. Previous trials of the intismeran-Keytruda combination operated at Phase 2, generating promising but preliminary signals. The Phase 3 results, announced via a pre-specified interim analysis while the trial remains ongoing, elevate the treatment from experimental curiosity to a candidate with regulatory submission potential.
The vaccine works through a mechanism distinct from chemotherapy and standard immunotherapy. Chemotherapy attacks both healthy and cancerous cells. Immunotherapy drugs like Keytruda release the brakes on the immune system broadly, allowing it to attack cancer more aggressively. Intismeran adds a third layer: it trains the immune system to recognize and target specific mutations found only on an individual patient’s tumor.
The process begins with tumor sequencing. After a melanoma is surgically removed, the tissue is analyzed to identify up to 34 unique mutations, called neoantigens, that distinguish the cancer cells from healthy tissue. Moderna then synthesizes a custom mRNA sequence encoding those neoantigens, packages it in a lipid nanoparticle, and delivers it back to the patient. The patient’s immune system reads the mRNA instructions, builds proteins matching the tumor mutations, and mounts a targeted immune response against any remaining cancer cells carrying those same mutations.
In the trial, patients received intismeran at a dose of 1 milligram every three weeks for up to nine doses, alongside approximately one year of Keytruda treatment. The control arm received Keytruda alone. No new safety signals were reported in the interim analysis.
Phase 2b Data Provides the Quantitative Baseline
While Moderna and Merck withheld specific numerical results from the Phase 3 interim analysis, stating that detailed data will be presented at an upcoming medical conference and submitted to regulators, the Phase 2b trial provides context for the scale of benefit the combination can deliver.
Five-year follow-up data from the Phase 2b KEYNOTE-942 trial, presented at the 2026 American Society of Clinical Oncology Annual Meeting in June, showed that patients receiving intismeran plus Keytruda experienced a 49% reduction in the risk of cancer recurrence or death compared with patients receiving Keytruda alone. The combination also produced a 59% reduction in the risk of distant metastasis or death, meaning the cancer spreading to organs or tissues beyond the original tumor site.
Those figures are significant in the context of melanoma treatment. Patients with surgically resected high-risk melanoma, defined as cases where the tumor has grown deep into the skin, spread to nearby lymph nodes, or metastasized, face substantial recurrence rates even after successful surgery. The standard adjuvant treatment has been Keytruda alone. The Phase 3 results suggest that adding intismeran to that standard of care produces a measurable improvement in how long patients remain cancer-free.
Georgina Long, the trial’s principal investigator and medical director of the Melanoma Institute Australia, described the results as having the potential to establish “a new treatment paradigm in the adjuvant melanoma setting.”
The Pipeline Extends Well Beyond Melanoma
The melanoma trial is the most advanced program in a broader partnership between Moderna and Merck that spans multiple cancer types. The two companies have eight total Phase 2 and Phase 3 studies underway, applying the same personalized neoantigen approach to different tumor types at various stages of clinical development.
Late-stage trials are underway in non-small cell lung cancer, the most common form of lung cancer and one of the leading causes of cancer death globally. Mid-stage studies are testing the combination in patients with bladder cancer and renal cell carcinoma. Earlier-stage trials are exploring its use in pancreatic and stomach cancers. Moderna President Stephen Hoge indicated that multiple trial results across these programs are expected within the next one to two years.
The competitive landscape is also developing. Roche and BioNTech, the German biotech company whose mRNA platform underpinned the Pfizer COVID-19 vaccine, are testing a similar personalized neoantigen therapy called autogene cevumeran in mid-stage studies for colon and pancreatic cancer patients who have undergone surgery. The Moderna-Merck melanoma readout puts their program ahead in the regulatory race, but the broader field of personalized cancer vaccines is expanding across multiple companies and tumor types.
Stock Movements Reflect Investor Recalibration
The market response to the announcement was immediate and dramatic. Moderna’s stock surged as much as 177% in trading on August 19, closing at $174 per share. Merck shares rose approximately 13%. The magnitude of Moderna’s move reflects how significantly the company’s valuation had contracted since the pandemic era, when its COVID-19 vaccine generated tens of billions in revenue.
Moderna has faced sustained pressure as COVID-19 vaccine demand declined. The U.S. Department of Health and Human Services last year canceled a $590 million contract with Moderna to develop an mRNA-based vaccine against pandemic influenza, and subsequently announced it would no longer fund mRNA research through the Biomedical Advanced Research and Development Authority. The cancer vaccine success provides Moderna with a revenue pathway independent of infectious disease and government pandemic preparedness contracts.
Barclays analysts estimate the therapy could generate approximately $3 billion in melanoma treatment revenue by 2035. Leerink Partners analyst Daina Graybosch characterized the Phase 3 results as a “historic cancer vaccine success.” Moderna expects that thousands of melanoma patients could benefit within the first few years of regulatory approval, though the timeline for that approval depends on the regulatory submission process and review by the Food and Drug Administration.
The company has been diversifying its portfolio beyond COVID-19. Moderna recently received FDA approval for an mRNA-based flu vaccine and has experimental candidates in development for norovirus and Lyme disease. The cancer vaccine program, however, represents the largest potential revenue opportunity in the company’s pipeline outside of respiratory vaccines.
What Remains Unknown
Several critical questions remain unanswered ahead of the full data release. The companies have not disclosed the specific hazard ratios, median survival times, or detailed subgroup analyses from the Phase 3 interim analysis. Those figures will determine how regulators evaluate the treatment’s benefit-risk profile and whether the data support accelerated approval or require a standard review timeline.
Overall survival, a secondary endpoint that measures whether patients live longer overall rather than simply remaining cancer-free longer, has not yet been reported. The trial will continue to evaluate this and other endpoints as follow-up data accumulates. The distinction matters: a treatment that delays recurrence but does not ultimately extend life carries a different clinical and regulatory profile than one that does both.
The manufacturing and delivery logistics of personalized cancer vaccines also present practical challenges at scale. Each dose of intismeran requires individual tumor sequencing, custom mRNA synthesis, and patient-specific production, a fundamentally different manufacturing model than the mass-produced, one-size-fits-all approach used for COVID-19 vaccines. How efficiently Moderna and Merck can scale that process will influence both the therapy’s accessibility and its commercial viability.
Disclaimer: This article is for informational and educational purposes only and does not constitute medical, financial, investment, or professional advice. Intismeran remains an investigational treatment and has not been approved for general use by the U.S. Food and Drug Administration. Clinical trial results may change as additional data becomes available, and past or interim results do not guarantee future outcomes. Readers should consult qualified healthcare professionals regarding medical decisions and conduct their own research or consult a licensed financial adviser before making investment decisions.
FAQs
What is intismeran and how does it work?
Intismeran is a personalized mRNA cancer vaccine developed jointly by Moderna and Merck. It works by sequencing a patient’s surgically removed tumor to identify up to 34 unique mutations, then synthesizing a custom mRNA sequence that trains the immune system to recognize and attack cancer cells carrying those specific mutations. It is administered alongside Merck’s immunotherapy drug Keytruda.
What did the Phase 3 trial find?
The Phase 3 INTerpath-001 trial, involving 1,137 patients with surgically resected high-risk melanoma, found that intismeran plus Keytruda achieved statistically significant improvements in recurrence-free survival and distant metastasis-free survival compared with Keytruda alone. Earlier Phase 2b data showed a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis or death risk.
Has the FDA approved intismeran?
No. Intismeran remains investigational and has not been approved by the Food and Drug Administration. Moderna and Merck have stated they plan to submit the findings to regulatory authorities and present full results at an upcoming medical conference. The timeline for potential approval has not been disclosed.
What other cancers are being studied with this approach?
Moderna and Merck have eight total Phase 2 and Phase 3 studies underway. Beyond melanoma, late-stage trials are testing intismeran in non-small cell lung cancer. Mid-stage studies are evaluating the treatment in bladder cancer and renal cell carcinoma, with early-stage trials in pancreatic and stomach cancers. Multiple results across these programs are expected within the next one to two years.
